Melbourne-based Sienna Cancer Diagnostics is a public listed company with global operations. Head office and laboratories are located within the Small Technologies Cluster, a successful and thriving environment where a number of biotechnology and other high technology businesses have their research and development, commercialisation and manufacturing operations.
Sienna's focus is in creating a portfolio of unique and clinically useful tests for the pathology diagnostics market and clinical diagnostic laboratories worldwide.
In July 2020, the company was acquired by BARD1 Life Sciences.
